Study Title
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Study Details
Description:
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.
Sponsor:
Aiwu Ruth He, MD
Contacts:
Aiwu R He, MD, PhD (Principal Investigator)rmottier@hoosiercancer.org
317-634-5842 ext 60
Government Study Link:
NCT04541173 - Click here to see study onClinicalTrials.gov